The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MTSR | N/A | N/A | N/A | +98% |
| S&P | +16.9% | +95.99% | +14.39% | +12% |
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | -250.0% |
| Market Cap | $2.99B | 0.0% |
| Market Cap / Employee | $27.42M | 0.0% |
| Employees | 109 | 0.0% |
| Net Income | -$68.72M | -157.1% |
| EBITDA | -$71.99M | -171.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $530.92M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.32M | 0.0% |
| Short Term Debt | $1.04M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -42.06% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$59.14M | -191.8% |
| Operating Free Cash Flow | -$58.94M | -191.4% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | -11.28 | 5.90 | - | ||
| Price to Tangible Book Value | -8.31 | 7.24 | - | ||
| Enterprise Value to EBITDA | -34.60 | -34.10 | - | ||
| Total Debt | $0.95M | $10.19M | $10.05M | $1.36M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
